We adopted a meta-analysis approach to evaluate the effectiveness of calcium supplements on gestational hypertensive disorders and related maternal and neonatal outcomes. Literatures were searched in PubMed, EMBASE, Springer link, and Cochrane clinical controlled trials (CCRTs) database from inception to Jan. 2014. The quality assessment was done by two reviewers independently. A total of 11 studies (8221 subjects treated with calcium supplements and 8219 treated with placebo) were included in present meta-analysis. Significantly lower incidence of pregnancy induced hypertension (PIH) (RR = 0.72, 95% CI: 0.57-0.90, P = 0.004) and preeclampsia (RR = 0.54, 95% CI: 0.38-0.76, P = 0.0004) were presented in the calcium supplementation group. Besides, calcium supplementation significantly increase birth weight (MD = 69.35g, 95% CI: 20.00, 118.70, P = 0.006). However, there was no statistically significant difference between the groups in severe preeclampsia (P = 0.05), preterm birth (P = 0.13), low birth weight babies (P = 0.20), and perinatal mortality (P = 0.24). Calcium supplementation could reduce the risk of PIH and preeclampsia for pregnant women, meanwhile, significantly increase birth weight. However, there are no additional benefits for calcium supplementation in preventing severe preeclampsia, preterm birth, low birth weight, and perinatal mortality. In summary, calcium supplementation is an effective measure to reduce the risk of gestational hypertensive disorders especially in populations with low-dietary calcium intake.